This review explores the cardiovascular consequences of opioids and the contributions of off-target electrophysiologic properties to mortality, and provides practical safety recommendations.
The researchers studied mothers of infants with neonatal abstinence syndrome and/or prenatal substance exposure and whether they received treatment for substance use disorder.
More than 50% of patients with alcohol use disorder develop alcohol withdrawal symptoms within hours of discontinuing or decreasing alcohol use.
Researchers attempted to determine if medications for opioid use disorder integrated with infectious disease measures can lead to better infectious disease outcomes.
Study data published in PLoS One suggest that gender minority (GM) adolescents may engage in substance use more frequently than their peers.
With overdose deaths spiking during the early months of the COVID-19 pandemic, data was not disaggregated by month, race/ethnicity, or other social attributes. The study investigators utilized data from emergency medical services in racial/ethnic, social, and geographic trends in overdose-related cardiac arrests.
With drug use rising, society requires new prevention approaches. The not-for-profit Center for US Policy (CUSP) announced a national contest to identify the “Top 5 Emerging Practices to Prevent Substance Misuse.”
The FDA has accepted for review the resubmitted NDA for Zimhi, a high-dose naloxone injection product candidate for the treatment of opioid overdose.
There is large variation in buprenorphine prescribing, with a small percentage of clinicians accounting for most buprenorphine treatment in the United States.
Older adults with functional impairments may be more likely to misuse prescription drugs and to use medical cannabis.
